12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d8876117e196">To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1-selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an inadequate response to methotrexate (MTX). </p>

          Related collections

          Author and article information

          Journal
          Arthritis & Rheumatology
          Arthritis Rheumatol
          Wiley
          2326-5191
          2326-5205
          July 09 2019
          July 09 2019
          Affiliations
          [1 ]University of Texas Southwestern Medical Center Metroplex Clinical Research Center Dallas TexasUSA
          [2 ]AbbVie Inc North ChicagoIllinoisUSA
          [3 ]Organización Medica de Investigación Buenos AiresArgentina
          [4 ]Laval University QuebecCanada
          [5 ]Spire Sciences Inc Boca RatonFloridaUSA
          [6 ]Pôle de Recherche en Rhumatologie Institut de Recherche Expérimentale et Clinique UCL Saint‐Luc BrusselsBelgium
          [7 ]Cabrini Medical Center Malvern Australia
          [8 ]Division of Immunology &amp; Rheumatology, Stanford University School of Medicine Palo Alto California USA
          Article
          10.1002/art.41032
          31287230
          4ff9816e-2b31-4893-aa08-7f5a6937f26d
          © 2019

          http://doi.wiley.com/10.1002/tdm_license_1.1

          History

          Comments

          Comment on this article